Researchers evaluated protection conferred by a single COVID-19 mRNA vaccine dose vs a 2-dose series in the setting of high preexisting SARS-CoV-2 immunity.

A year after the first samRNA vaccine approval, experts say others are likely to face scientific and regulatory hurdles.

Updated COVID-19 vaccines targeting JN.1-lineage omicron variants of the coronavirus are now available in the U.S. for the ...

COVID-19 vaccination is associated with a reduced risk for most CV events, but with slightly increased risks for extrasystoles and transient ischemic attack, as well as myocarditis and pericarditis ...

COVID-19 2024–2025 vaccines are recommended for everyone aged 6 months and older, with vaccines targeting the JN.1 and KP.2 strains of SARS-CoV-2.

Northwestern filed a lawsuit against Moderna Wednesday alleging the company misused the University’s patented lipid ...

Moderna is focusing on respiratory vaccines to sustain revenue streams amid COVID-19 declines. See more on MRNA stock and its ...

The UK Government has recommended offering a COVID-19 booster vaccination in autumn, 2024, to individuals at high risk of ...

We recently published a list of 10 Best Depressed Stocks To Buy Heading into 2025. In this article, we are going to take a ...

A new vaccine provides hope for treating and even preventing the highly contagious and difficult-to-treat Clostridioides ...

Northwestern University has filed a lawsuit against Moderna, alleging the company used its patented lipid nanoparticle ...

mRNA vaccines, pivotal in the fight against COVID-19, are now emerging as a promising innovation in cancer treatment. As clinical trials advance, Ben Hargreaves finds the technology is poised to ...